Coriolis Pharma extends its service portfolio by integrating RheaVita’s single vial unit (SVU) technology for continuous and controlled freeze-drying to stabilize novel modalities as part of biologics drug product development for clients.

RheaVita, a company pioneering continuous freeze-drying technology for biopharmaceutical products, announced today that the company has closed a EUR 2.5 million Series A Financing.